Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2012-02-08 Major Shareholding Noti…
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
SC 13G/A Filing
Major Shareholding Notification
2012-02-08 English
SC 13G/A Filing
Major Shareholding Notification
2012-02-07 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a press release announcing the completion of a Phase 3 registration program for a drug and mentions a conference call to discuss the announcement. There are no detailed financial statements or comprehensive financial analysis present. The document is relatively short (2777 characters) and primarily serves as an announcement of an event and a press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2012-01-09 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on material events. The content describes the entry into and termination of a material definitive agreement between Theravance and Astellas Pharma, including details about the license agreement for VIBATIV and its termination. There is no financial statement or earnings data presented, nor is this a report of voting results, management changes, or other categories. The document primarily announces a material contract amendment and termination, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories. The document length is 5835 characters, which is sufficient for a full 8-K report but the content is focused on contract amendments and termination announcements, not financial results or other report types.
2012-01-06 English
4 Filing
Director's Dealing
2011-12-13 English
8-K/A Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is a current report used to disclose material events. The content describes an event related to manufacturing and distribution issues of a drug product, including letters sent to wholesalers, distributors, and healthcare professionals. There are no financial statements or detailed financial data presented. The document is an event disclosure rather than a financial report or earnings release. It does not fit categories like Annual Report, Earnings Release, or Interim Report. It is a regulatory announcement of a significant event affecting the company, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous SEC filings that do not fit other categories.
2011-12-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.